Nephrogenic fibrosing dermopathy: a case study.
While no information indicates that gadolinium contrast is a sole causative agent, nurses should assist patients on hemodialysis and those with moderate or end stage renal disease in making informed decisions regarding the clinical necessity for any imaging that requires the use of a gadolinium contrast. According to the FDA advisory, only those tests in which the outcome would outweigh the potential risk should be conducted (FDA, 2007a).
Sego
Sherril
S
Kansas City Veterans Affairs Medical Center, Kansas City, MO, USA. sherrilsego@comcast.net
D000203:Activities of Daily Living; D000328:Adult; D001706:Biopsy; D004802:Eosinophilia / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D017809:Fatal Outcome; D005260:Female; D005355:Fibrosis; D019786:Gadolinium DTPA / Q000009:adverse effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D009203:Myocardial Infarction / Q000209:etiology; D009730:Nursing Assessment; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010347:Patient Care Planning; D010353:Patient Education as Topic; D012871:Skin Diseases / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control
D019786:Gadolinium DTPA